According to recent disclosures, Dingdang Health Technology Group (09886) anticipates its net loss for the year ended December 31, 2025 (FY2025) to narrow by more than 80% compared to the FY2024 net loss of approximately RMB380.00 million. The improvement is largely attributed to a notable decrease in impairment losses of goodwill and other intangible assets, which amounted to RMB198.90 million and RMB6.80 million, respectively, in FY2024.

The Group cites strategic optimization in major cities such as Beijing, Shanghai, and Shenzhen, along with an expanded smart pharmacy network, as factors bolstering operational efficiency. Additionally, strengthened supply chain service capabilities and a shift toward higher-margin products contributed to profitability gains. Benefiting from these measures, Dingdang Health Technology Group expects an adjusted net profit of no less than RMB5.00 million for FY2025, a turnaround from an adjusted net loss of approximately RMB57.20 million in FY2024. The company plans to release its final annual results for FY2025 in March 2026.